RISK FACTORS

PATHOPHYSIOLOGY

REMEDIAL STEPS

  1. Home
  2. IVIG

IVIG

 

  1. Raju R, Dalakas M. Gene expression profile in the muscles of patients with inflammatory myopathies: effect of therapy with IVIG and biological validation of clinically relevant genes. Brain August 2005 128(8)1887-1896. Found at http://brain.oxfordjournals.org/content/128/8/1887.short
  2. Dalakas M. Intravenous Immunoglobulin in Autoimmune Neuromuscular Diseases. JAMA. 2004;291(19):2367-2375. Found at http://jama.jamanetwork.com/article.aspx?articleid=198740
  3. Cherin P, Pelletier S, Teixeira A. Results and long-term followup of intravenous immunoglobulin infusions in chronic, refractory polymyositis: an open study with 35 adult patients. Arthritis Rheum.2002 Feb;46(2):467-74. Found at http://www.ncbi.nlm.nih.gov/pubmed/11840450?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum#
  4. Cherin P, Herson S, Wechsler B, et al. Effect of intravenous gammaglobulin therapy in chronic refractory polymyositis and dermatomyositis: an open study with 20 adult patients. American Journal of Medicine Volume 91, issue 2, pp162-168, August 1991
  5. Nobuyuki M, Hara M. Effects of intravenous immunoglobulin therapy in Japanese patients with polymyositis and dermatomyositis resistant to corticosteroids: a randomized double-blind placebo-controlled trial. Mod Rheumatol (2012) 22:382–393, as found at http://rd.springer.com/article/10.1007/s10165-011-0534-4
  6. Helmers S, Dastmalchi M, Alexanderson H et al. Ann Rheum Dis. 2007 October; 66(10): 1276–1283. Found at http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1994317/,.










loading...